About
Professional SummaryDr. Marc Poirot is Research Director at the Institute National de la Santé et de la Recherche Medicale (INSERM). He Heads the team Sterol Metabolism and Therapeutic Innovations in Oncology (Toulouse, France) with Dr. Sandrine Silvente-Poirot at the Cancer Research Center of Toulouse. He received a PhD in Chemical Biology (1991) from the University of Toulouse (France). He did a Post-doctorate at Sanofi in 1991 before becoming tenured at INSERM. He was Visiting Scientist in the laboratory of Dr Stoney S. Simons Jr (NIDDK/NIH, Bethesda, USA) to study Steroid Hormone Receptors. Since then, his research has focused on the identification of off-targets of the anti-tumor drug tamoxifen, which led to the definition of the importance of Cholesterol Metabolism in the Pharmacology of Antiestrogens. He trained 10 of postgraduate students. He has published 68 SCI journal paper. He also served as an evaluation expert for organizations. He is co-founder of the Biotech Company Affichem, which develops small natural molecules for therapeutic applications. He is member of the executive board and chairman of the scientific board of Affichem, Innovative, translational and longstanding research has ever been a pursuit in his academic career. He is associate editor for Frontiers in Nutrition, Frontiers in Pharmacology, Frontiers in Chemistry, Frontiers in Oncology, Nature publishing group. He is also serving as reviewer and editor of number of journals. He is member of Groupe de recherche sur les lipides, Société Française de Chimie Therapeutique, American Association for Cancer Research, American Society of Pharmacology and Experimental Therapeutics, European Network on Oxysterol Research, and Asian Council of Science Editors.
Education
Academic Background-
Ph.D. Universite Paul Sabatier, Toulouse, France Chemistry | Completed: 1991
Editorial Services
Editorial & Publishing RolesPublications (101)
Selected Scholarly Contributions
The Phospholipid Bis(monoacylglycero)Phosphate Confers Antitumour Immunogenicity to Exosomes Secreted by Dendrogenin A, Which Activates Its Biosynthesis in Tumour Cells
2026
Selective
DHCR7
inhibition versus
AEBS
modulation: Mechanistic implications for tamoxifen effects in
AML
2026
2026
Dairy Processing and Breast Cancer: A Hypothesis-Generating Framework Linking Bioactive Lipid Derivatives to Epidemiological Heterogeneity
2026
The WISDOM Trial and the Evidence Base for Risk-based Breast Cancer Screening
2026
Targeting NR1H/liver X receptor with dendrogenin A differentiates tumor cells to activate a new secretory pathway releasing immunogenic anti-tumor vesicles enriched in LC3-II-associated exosomes
2023
An Update on Tamoxifen and the Chemo-Preventive Potential of Vitamin E in Breast Cancer Management
2023
27-Hydroxylation of oncosterone by CYP27A1 switches its activity from pro-tumor to anti-tumor
2023
Pharmacologic and genetic inhibition of cholesterol esterification enzymes reduces tumour burden: A systematic review and meta-analysis of preclinical models
2022
2022
Targeting the liver X receptor with dendrogenin A differentiates tumour cells to secrete immunogenic exosome‐enriched vesicles
2022
In vitro and In vivo oxidation and cleavage products of tocols: From chemical tuners to “VitaminEome” therapeutics. A narrative review
2022
The 5,6‐epoxycholesterol metabolic pathway in breast cancer: Emergence of new pharmacological targets
2021
Dendrogenin A Enhances Anti-Leukemic Effect of Anthracycline in Acute Myeloid Leukemia
2020
2020
Dendrogenin a synergizes with cytarabine to kill acute myeloid leukemia cells in vitro and in vivo.
Marc Poirot
2020
HPLC Analysis and Skin Whitening Effects of Umbelliprenin-containing Extracts of Anethum Graveolens, Pimpinella Anisum, and Ferulago Campestris
2019
Flavonoids differentially modulate liver x receptors activity—structure-function relationship analysis.
Marc Poirot
2019
The cholesterol-derived metabolite dendrogenin a functionally reprograms breast adenocarcinoma and undifferentiated thyroid cancer cells.
Marc Poirot
2019
Oxysterols: an expanding family of structurally diversified bioactive steroids.
Marc Poirot
2019
A fast uplc–hilic method for an accurate quantification of dendrogenin a in human tissues.
Marc Poirot
2019
Natural and semisynthetic oxyprenylated aromatic compounds as stimulators or inhibitors of melanogenesis.
Marc Poirot
2019
Bryonolic Acid Blocks Cancer Cell Clonogenicity and Invasiveness through the Inhibition of Fatty Acid: Cholesteryl Ester Formation
2018
2018
Ligand-dependent transcriptional induction of lethal autophagy: A new perspective for cancer treatment.
Marc Poirot
2018
The tumor-suppressor cholesterol metabolite, dendrogenin A, is a new class of LXR modulator activating lethal autophagy in cancers.
Marc Poirot
2018
Chemistry, biochemistry, metabolic fate and mechanism of action of 6-oxo-cholestan-3β, 5α-diol (OCDO), a tumor promoter and cholesterol metabolite.
Marc Poirot
2018
Extracellular vesicles: Lipids as key components of their biogenesis and functions.
Marc Poirot
2018
The effects of cholesterol-derived oncometabolites on nuclear receptor function in cancer.
Marc Poirot
2018
2017
Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study.
Marc Poirot
2017
Improvement of 5, 6α-epoxycholesterol, 5, 6β-epoxycholesterol, cholestane-3β, 5α, 6β-triol and 6-oxo-cholestan-3β, 5α-diol recovery for quantification by GC/MS.
Marc Poirot
2017
Improving the efficacy of hormone therapy in breast cancer: The role of cholesterol metabolism in SERM-mediated autophagy, cell differentiation and death.
Marc Poirot
2017
Quantitative analysis of the tumor suppressor dendrogenin A using liquid chromatography tandem mass spectrometry.
Marc Poirot
2017
Identification of a tumor-promoter cholesterol metabolite in human breast cancers acting through the glucocorticoid receptor.
Marc Poirot
2017
From tamoxifen to dendrogenin A: The discovery of a mammalian tumor suppressor and cholesterol metabolite
2016
When cholesterol meets histamine, it gives rise to dendrogenin A: A tumour suppressor metabolite1.
Marc Poirot
2016
Guidelines for the use and interpretation of assays for monitoring autophagy.
Marc Poirot
2016
2015
Dendrogenin A: A mammalian metabolite of cholesterol with tumor suppressor and neurostimulating properties.
Marc Poirot
2015
Human monocyte recognition of adenosine-based cyclic di-nucleotides unveils the A2a GPCR tonic inhibition of mitochondrial-induced cell death.
Marc Poirot
2015
The novel steroidal alkaloids dendrogenin A and B promote proliferation of adult neural stem cells.
Marc Poirot
2014
2014
Cholesterol and cancer in the balance.
Marc Poirot
2014
Exosomes as new vesicular lipid transporters involved in cell-cell communication and various pathophysiologies.
Marc Poirot
2014
Emerging concepts on the role of exosomes in lipid metabolic diseases.
Marc Poirot
2014
Progesterone and a phospholipase inhibitor increase the endosomal bis(monoacylglycero)phosphate content and block HIV viral particle intercellular transmission.
Marc Poirot
2013
Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolism.
Marc Poirot
2013
Oxysterols and related sterols: Implication in physiopathology and pharmacology.
Marc Poirot
2013
5,6-Epoxy-cholesterols contribute to the anticancer pharmacology of Tamoxifen in breast cancer cells.
Marc Poirot
2013
MAPK14 p38alpha confers Irinotecan resistance to tp53-defective cells by inducing survival autophagy.
Marc Poirot
2012
Identification of a new stilbene-derived inducer of paraoxonase 1 and ligand of the Aryl hydrocarbon Receptor.
Marc Poirot
2012
Guidelines for the use and interpretation of assays for monitoring autophagy.
Marc Poirot
2012
Cholesterol metabolism and cancer: The good, the bad and the ugly.
Marc Poirot
2012
Cholesterol metabolism and resistance to tamoxifen in breast cancers.
Marc Poirot
2012
2012
Cholesterol-5,6-epoxides: Chemistry, biochemistry, metabolic fate and cancer.
Marc Poirot
2012
Surprising unreactivity of cholesterol-5,6-epoxides towards nucleophiles.
Marc Poirot
2012
Technical note: Hapten synthesis, antibody production and development of an enzyme-linked immunosorbent assay for detection of the natural steroidal alkaloid Dendrogenin A.
Marc Poirot
2012
Four decades of discovery in breast cancer research and treatment--an interview with V. Craig Jordan. Interview by Marc Poirot.
Marc Poirot
2011
Importance of cholesterol and oxysterols metabolism in the pharmacology of tamoxifen and other AEBS ligands.
Marc Poirot
2011
Exosomes as intercellular signalosomes and pharmacological effectors.
Marc Poirot
2011
Development of a new radioligand for cholecystokinin receptor subtype 2 scintigraphy: From molecular modeling to In vivo evaluation.
Marc Poirot
2010
Peptidic targeting in nuclear oncology: Interest of molecular modelling.
Marc Poirot
2010
Exosomes account for vesicle-mediated transcellular transport of activatable phospholipases and prostaglandins.
Marc Poirot
2010
Auraptene is an inhibitor of cholesterol esterification and a modulator of estrogen receptors.
Marc Poirot
2010
Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands.
Marc Poirot
2010
Synthesis, characterization and In vitro evaluation of new oxorhenium- and oxotechnetium-CCK4 derivatives as molecular imaging agents for CCK2-receptor targeting.
Marc Poirot
2010
Synthesis of new alkylaminooxysterols with potent cell differentiating activities: Identification of leads for the treatment of cancer and neurodegenerative diseases.
Marc Poirot
2009
Tamoxifen and AEBS ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation.
Marc Poirot
2009
Signaling through cholesterol esterification: A new pathway for the cholecystokinin 2 receptor involved in cell growth and invasion.
Marc Poirot
2009
Ligands of the antiestrogen-binding site induce active cell death and autophagy in human breast cancer cells through the modulation of cholesterol metabolism.
Marc Poirot
2009
Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism.
Marc Poirot
2008
Preclinical evaluation of new radioligand of cholecystokinin/gastrin receptors in endocrine tumors xenograft nude mice.
Marc Poirot
2007
Resveratrol and its derivatives: A new family of antagonists of the aryl hydrocarbon receptor.
Marc Poirot
2006
The prototypical inhibitor of cholesterol esterification, Sah 58-035 [3-[decyldimethylsilyl]-N-[2-(4-methylphenyl)-1-phenylethyl]propanamide], is an agonist of estrogen receptors.
Marc Poirot
2006
Insights into the cholecystokinin 2 receptor binding site and processes of activation.
Marc Poirot
2006
Synthesis and biological properties of new stilbene derivatives of resveratrol as new selective aryl hydrocarbon modulators.
Marc Poirot
2005
Farnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways.
Marc Poirot
2005
Multiple targeting by the antitumor drug tamoxifen: a structure-activity study.
Marc Poirot
2004
Molecular characterization of the microsomal tamoxifen binding site.
Marc Poirot
2004
Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells.
Marc Poirot
2004
Insulin and estrogen receptor ligand influence the FGF-2 activities in MCF-7 breast cancer cells.
Marc Poirot
2003
Contrasting effects of prenyltransferase inhibitors on estrogen-dependent cell cycle progression and estrogen receptor-mediated transcriptional activity in MCF-7 cells.
Marc Poirot
2003
High tumorigenic potential of a constitutively active mutant of the cholecystokinin 2 receptor.
Marc Poirot
2003
Identification of tyrosine 189 and asparagine 358 of the cholecystokinin 2 receptor in direct interaction with the crucial C-terminal amide of cholecystokinin by molecular modeling, site-directed mutagenesis and structure/affinity studies.
Marc Poirot
2003
Identification of two tamoxifen target proteins by photolabeling with 4-(2-morpholinoethoxy)benzophenone.
Marc Poirot
2002
Alteration of plasmalemmal caveolae mimics endothelial dysfunction observed in atheromatous rabbit aorta.
Marc Poirot
2001
Synthesis, binding and structure-affinity studies of new ligands for the microsomal anti-estrogen binding site (AEBS).
Marc Poirot
2000
Structural similitudes between cytotoxic antiestrogen-binding site (AEBS) ligands and cytotoxic sigma receptor ligands. Evidence for a relationship between cytotoxicity and affinity for AEBS or sigma-2 receptor but not for sigma-1 receptor.
Marc Poirot
1999
Modifications of benzylphenoxy ethanamine antiestrogen molecules: Influence affinity for antiestrogen binding site (AEBS) and cell cytotoxicity.
Marc Poirot
1999
Different populations of progesterone receptor-steroid complexes in binding to specific DNA sequences: Effects of salts on kinetics and specificity.
Marc Poirot
1998
Microsomal epoxide hydrolase of rat liver is a subunit of theanti-oestrogen-binding site.
Marc Poirot
1998
Characterization of the membranous antiestrogen binding protein: II Purification to homogeneity.
Marc Poirot
1994
Characterization of the membranous antiestrogen binding protein: I. Partial purification of the protein in its active state.
Marc Poirot
1994
Characterization of a benzyl-phenoxy-ethanamine binding protein in Trypanosoma equiperdum and the possible relation between binding affinity and trypanocidal activity.
Marc Poirot
1993
Cytosolic type II estrogen binding site in rat uterus: Specific photolabeling with estrone.
Marc Poirot
1992
A Mr 45,000 secreted protein is specifically induced by tamoxifen: Identification in the human breast cancer cell line, MCF-7, adapted to grow in chemically defined medium.
Marc Poirot
1991
The anti-proliferative properties of 4-benzylphenoxy ethanamine derivatives are mediated by the anti-estrogen binding site (ABS), whereas the anti-estrogenic effects of trifluopromazine are not.
Marc Poirot
1990
A potent and selective photoaffinity probe for the anti-estrogen binding site of rat liver.
Marc Poirot
1990
Further evidence for a biological role of anti-estrogen-binding sites in mediating the growth inhibitory action of diphenylmethane derivatives.
Marc Poirot
1988